Outpatient Oncology Infusion Market Size - By Product (Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors), Application (Lung Cancer, Liver Cancer, Breast Cancer, Prostate Cancer), Therapy (Chemotherapy), Mode & Forecast, 2024 – 2032

Outpatient Oncology Infusion Market Size

Outpatient Oncology Infusion Market size was valued at USD 2.4 billion in 2023 and is expected to exhibit growth at a CAGR of 10.6% from 2024 to 2032. High market growth is driven by technological advancements in infusion pumps, the increasing prevalence of cancer, and the expansion of healthcare policies and insurance coverage. These factors support the shift toward outpatient treatments, which are favored for their cost-effectiveness and efficiency.
 

Cancer is a major public health issue across the globe. This is owing to the surging cancer cases and mortality rate. For instance, according to the American Cancer Society, in 2021, around 608,570 cancer deaths occurred in the U.S. Also stated that breast cancer is the most common type of cancer on the list, with 284,200 new cases in the U.S. 2021. Prostate cancer and lung cancer are the next most common cancers. Therefore, the high burden of cancer is increasing the demand for infusion therapy and drug infusion system, thereby contributing to the market growth.
 

Outpatient oncology infusion is the administration of chemotherapy, cancer immunotherapy, or other cancer treatments in an outpatient setting rather than in a hospital. Patients visit a specialized clinic or infusion center to receive their medications intravenously. This approach allows patients to spend less time in medical facilities and more time at home, improving their quality of life.
 

Outpatient Oncology Infusion Market Trends

The market is experiencing several key trends driving its growth and evolution. These include the increasing geriatric population and a shift in patient preferences towards outpatient facilities due to enhanced comfort, cost efficiency, and technological advancements. Additionally, changes in healthcare policies, along with improved survival rates, are expected to have a positive impact on the market during the forecast period.
 

• Governments worldwide have been actively working to raise awareness about cancer treatment, aiming to reduce the disease burden and support the growth of the oncology outpatient infusion market. For example, in February 2022, the U.S. government relaunched the Cancer Moonshot program, with a mission to accelerate progress in cancer research and treatment. The program sets ambitious goals, such as reducing cancer death rates by at least 50% over the next 25 years. Such initiatives, which focus on increasing disease awareness, are expected to drive market growth.
   
• Government programs are instrumental in driving the market's expansion by implementing policies and initiatives that improve accessibility, affordability, and the quality of care.
   

Outpatient Oncology Infusion Market Analysis

Based on product, the market is classified into infusion pumps

intravenous sets, IV cannulas, and needleless connectors. The infusion pumps segment generated the highest revenue of USD 1.2 billion in 2023.
 

• The adoption of IV infusion pumps for cancer therapies at outpatient facilities is increasing due to their precision in drug delivery, ability to administer complex chemotherapy regimens, and improved patient outcomes. Further, infusion pumps provide continuous and controlled delivery of chemotherapeutic agents, reducing dosage errors and enhancing treatment efficacy.
   
• Additionally, advancements in pump technology, including programmable and smart pumps, have enhanced their reliability and ease of use, which is expected to further drive segment growth during the forecast period. For instance, in April 2024, Baxter International Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software, an advanced infusion pump featuring intelligent programming capabilities.
   

Based on application, the outpatient oncology infusion market is classified into lung cancer, liver cancer, breast cancer, prostate cancer, and other cancers. The breast cancer segment dominated the market in 2023 with a market share of 20.5%.
 

• The growth of this segment can be attributed to high prevalence of breast cancer worldwide, diverse and advanced treatment options, patient preference for outpatient care, supportive care services, and patient education and support programs. For instance, as per Global Cancer Statistics 2022, 2.3 million new cases were diagnosed with female breast cancer in 2022.
   
• Additionally, the widespread and effective breast cancer screening programs lead to early detection. Early-stage breast cancer diagnosis often requires infusion-based treatments such as chemotherapy, targeted therapy, and hormone therapy, which are well-suited for administration in outpatient settings.
   

Based on therapy, the outpatient oncology infusion market is segmented into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. The targeted therapy segment dominated the market in 2023 and is anticipated to reach USD 1.5 billion by 2032.
 

• Targeted therapies, such as monoclonal antibodies and small molecule inhibitors, offer personalized treatment options based on the genetic makeup of a patient's tumor. This precision leads to improved efficacy and fewer side effects compared to traditional chemotherapy.
   
• Moreover, advances in molecular diagnostics have facilitated the identification of specific targets, enhancing the development and application of these therapies. The convenience of outpatient settings allows for easier administration and monitoring, further driving their popularity. Consequently, targeted therapies are transforming cancer treatment paradigms, contributing to better patient outcomes and higher adoption rates in outpatient oncology infusion.
   

Based on mode, the outpatient oncology infusion market is segmented into intramuscular (IM), intravenous (IV), subcutaneous, and other modes. The intravenous (IV) segment dominated the market in 2023 and is anticipated to reach USD 1.3 billion by 2032.
 

• IV administration allows for the direct delivery of chemotherapy and other therapeutic agents into the bloodstream, ensuring rapid and controlled absorption. Further, there is substantial rise in healthcare facilities that are providing IV therapies for cancer, which is further expected to accelerate segment growth. For instance, in July 2023, MidLantic Urology introduced IV immunotherapy infusion service for people suffering from bladder cancer.  
   
• The rise in targeted therapies, which often require IV administration, also contributes to the growing adoption of IV modes. These therapies are tailored to individual patients' genetic profiles, offering more effective and personalized treatment options.
   

North America outpatient oncology infusion market accounted for USD 1 billion market revenue in 2023 and is anticipated to grow at a CAGR of 10% between 2024 – 2032 period.
 

• The region's dominance can be attributed to several factors, including the rising prevalence of cancer, which is driving the demand for accessible and efficient treatment options, such as outpatient oncology infusion settings.
   
• North America benefits from a high level of cancer awareness and the importance of early diagnosis. Public health campaigns, screening programs, and advances in diagnostic technologies have contributed to earlier cancer detection, enabling timely intervention and treatment.
   

U.S. outpatient oncology infusion market is accounted for USD 949.2 million market revenue in 2023 and is anticipated to grow at a CAGR of 9.8% during the forecast period.
 

• The growth of the U.S. market is attributed to favorable healthcare policy, technological advancements, and patient preference. The Affordable Care Act and other healthcare reforms have expanded access to cancer treatment, encouraging the use of outpatient services to reduce overall healthcare costs.
   
• In addition, the high cost of inpatient care drives both providers and patients to seek more cost-effective solutions, with outpatient oncology infusion being a key component. Insurance companies in the U.S. also play a significant role by offering coverage for outpatient treatments, further promoting their adoption.
   

Germany outpatient oncology infusion market is projected to grow remarkably in the coming years.
 

• In Germany, the growing adoption of outpatient oncology infusion is driven by the country’s robust healthcare infrastructure and a strong focus on efficient resource utilization. The German healthcare system prioritizes high-quality care and cost-effectiveness, leading to a preference for outpatient settings where feasible. The establishment of specialized outpatient oncology centers equipped with advanced infusion technologies has further supported this transition.
   
• Additionally, the aging population and increasing cancer incidence in the country create a need for scalable and accessible treatment options, which outpatient infusion centers are well-positioned to provide.
   

Japan holds a dominant position in the Asia Pacific outpatient oncology infusion market.
 

• In Japan, the adoption of outpatient oncology infusion is driven by the country's demographic trends and consolidated healthcare infrastructure coupled with healthcare policies. Japan has one of the highest aging populations in the world, leading to a significant increase in cancer cases. Outpatient oncology infusion centers offer a practical solution to meet the growing demand for cancer treatment while managing healthcare costs.
   
• The Japanese healthcare system emphasizes accessibility and efficiency, with a strong network of outpatient clinics that provide comprehensive cancer care. Technological advancements in infusion therapies and the availability of targeted treatments that can be safely administered in outpatient settings contribute to this trend.
   

Outpatient Oncology Infusion Market Share

The market is characterized by the presence of several key players and a focus on technological innovation and strategic partnerships. These companies invest significantly in research and development to introduce advanced and intelligent infusion pumps and associated devices. Strategic initiatives such as mergers, acquisitions, and collaborations are common strategies employed by key players to strengthen their market position and expand their geographic footprint. Emerging players also play a crucial role in the market by introducing innovative solutions aimed at improving procedural outcomes and patient care in outpatient oncology infusion.
 

Outpatient Oncology Infusion Market Companies

Prominent players operating in the outpatient oncology infusion industry include:

• B. Braun Melsungen AG
• Baxter
• Becton, Dickinson, and Company
• Fresenius Kabi
• ICU Medical, Inc
• IRadimed Corporation
• Medtronic PLC
• Micrel Medical Devices SA
• Moog, Inc.
• Nipro Corporation
• Roche Diagnostics
• Smiths Medical
• Teleflex, Inc.
• Terumo Corporation
   

Outpatient Oncology Infusion Industry News:

• In December 2022, B. Braun Medical Inc. announced that the wireless devices of the Space Infusion Pump System earned certification to UL 2900-2-1 through UL Cybersecurity Assurance Program (UL CAP). The certification and recognition helped position B. Braun as a leader in providing secure and high-quality infusion pump systems and provided competitive advantage in the market.
   
• In May 2022, Fresenius Kabi closed the acquisition of Ivenix, Inc. This acquisition expanded the company’ infusion therapy product portfolio along with extension of its customer base.
   

The outpatient oncology infusion market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Infusion pumps
• Intravenous sets
• IV cannulas
• Needleless connectors

Market, By Application     

• Lung cancer
• Liver cancer
• Breast cancer
• Prostate cancer
• Other cancers

Market, By Therapy

• Chemotherapy
• Targeted therapy
• Immunotherapy
• Hormonal therapy

Market, By Mode

• Intramuscular (IM)
• Intravenous (IV)
• Subcutaneous
• Other modes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa